Kyverna’s investigational CAR-T therapy, mivocabtagene autoleucel (miv-cel) showed clinically meaningful mobility improvements in most stiff-person syndrome patients, prompting the company to plan an ...
Gilead Sciences, Inc. GILD announced that the FDA accepted Kite’s Biologics License Application (BLA) and granted Priority Review designation to investigational chimeric antigen receptor (CAR) T cell ...
Gilead Sciences, Inc.’s GILD Kite and Kiniksa Pharmaceuticals, Ltd. KNSA have entered a clinical collaboration to conduct a phase II, multicenter study on pipeline candidate mavrilimumab in ...
Bristol Myers Squibb and bluebird bio submitted a second Biologics License Application (BLA) to the FDA for idecabtagene vicleucel (ide-cel), the companies’ investigational B-cell maturation ...
A collection of the most-viewed Moneycontrol videos. Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results